Please use this identifier to cite or link to this item: https://doi.org/10.1186/1471-2407-11-430
Title: INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
Authors: Wu, Y.-L.
Park, K.
Soo, R.A. 
Sun, Y.
Tyroller, K.
Wages, D.
Ely, G.
Yang, J.C.-H..
Mok, T.
Issue Date: 7-Oct-2011
Citation: Wu, Y.-L., Park, K., Soo, R.A., Sun, Y., Tyroller, K., Wages, D., Ely, G., Yang, J.C.-H.., Mok, T. (2011-10-07). INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 11 : -. ScholarBank@NUS Repository. https://doi.org/10.1186/1471-2407-11-430
Abstract: Background: Previous research suggests the therapeutic cancer vaccine L-BLP25 potentially provides a survival benefit in patients with locally advanced unresectable stage III non-small cell lung carcinoma (NSCLC). These promising findings prompted the phase III study, INSPIRE, in patients of East-Asian ethnicity. East-Asian ethnicity is an independent favourable prognostic factor for survival in NSCLC. The favourable prognosis is most likely due to a higher incidence of EGFR mutations among this patient population.Methods/design: The primary objective of the INSPIRE study is to assess the treatment effect of L-BLP25 plus best supportive care (BSC), as compared to placebo plus BSC, on overall survival time in East-Asian patients with unresectable stage III NSCLC and either documented stable disease or an objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria following primary chemoradiotherapy. Those in the L-BLP25 arm will receive a single intravenous infusion of cyclophosphamide (300 mg/m2) 3 days before the first L-BLP25 vaccination, with a corresponding intravenous infusion of saline to be given in the control arm. A primary treatment phase of 8 subcutaneous vaccinations of L-BLP25 930 μg or placebo at weekly intervals will be followed by a maintenance treatment phase of 6-weekly vaccinations continued until disease progression or discontinuation from the study.Discussion: The ongoing INSPIRE study is the first large study of a therapeutic cancer vaccine specifically in an East-Asian population. It evaluates the potential of maintenance therapy with L-BLP25 to prolong survival in East-Asian patients with stage III NSCLC where there are limited treatment options currently available.Study number: EMR 63325-012. Trial Registration: Clinicaltrials.gov reference: NCT01015443. © 2011 Wu et al; licensee BioMed Central Ltd.
Source Title: BMC Cancer
URI: http://scholarbank.nus.edu.sg/handle/10635/110752
ISSN: 14712407
DOI: 10.1186/1471-2407-11-430
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

56
checked on Jul 3, 2020

WEB OF SCIENCETM
Citations

49
checked on Jul 3, 2020

Page view(s)

86
checked on Jun 27, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.